RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice. 2018

Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
Department of Hematology and Oncology, Dokkyo Medical University School of Medicine, Tochigi, Japan.

The RUNX1-EVI1 gene generated by the t(3;21) translocation encodes a chimeric transcription factor and is a causative gene in the development of de novo acute megakaryoblastic leukemia and leukemic transformation of hematopoietic stem cell tumors. Heterozygous RUNX1-EVI1 knock-in mice die in utero due to hemorrhage in the central nervous system and spinal cord and complete abolishment of definitive hematopoiesis in the fetal liver. On the other hand, the chimeric knock-in mouse develops acute megakaryoblastic leukemia. We created another mouse model of RUNX1-EVI1 using transplantation of retrovirus-infected bone marrow cells. Some mice transplanted with RUNX1-EVI1-expressing bone marrow cells developed acute megakaryoblastic leukemia within eight months, and the other non-leukemic mice showed thrombocytosis at around a year. In the non-leukemic mice, dysplastic megakaryocytes proliferated in the bone marrow and frequently infiltrated into the spleen, which was not associated with marrow fibrosis. In the leukemic mice, their tumor cells were positive for c-kit and CD41, and negative for TER119. Although they were negative for platelet peroxidase in the electron microscopic analysis, they had multiple centrioles in the cytoplasm, which are characteristic of megakaryocytes that undergo endomitosis. The leukemic cells were serially transplantable, and gene-expression analyses using quantitative RT-PCR arrays revealed that they showed significantly elevated expression of stem cell, primitive hematopoietic cell and endothelial cell-related genes compared with normal bone marrow cells. All these data suggested that RUNX1-EVI1 caused dysplastic hematopoiesis or leukemia of the megakaryocytic lineage and endowed gene expression profiles distinctive of immature hematopoietic cells.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008533 Megakaryocytes Very large BONE MARROW CELLS which release mature BLOOD PLATELETS. Megakaryocyte
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis
D000074008 MDS1 and EVI1 Complex Locus Protein A DNA binding protein, transcriptional regulator, and proto-oncogene protein that contains 10 CYS2-HIS2 ZINC FINGERS. It functions as a positive or negative regulator of expression for target genes involved in organism development. Ecotropic Virus Integration Site 1 Protein Homolog,MECOM Protein,Myelodysplasia Syndrome-Associated Protein 1,Zinc Finger Protein Evi1,Myelodysplasia Syndrome Associated Protein 1
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015514 Oncogene Proteins, Fusion The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin. Chimeric Oncogene Proteins,Chimeric Proteins, Oncogene,Fusion Proteins, Oncogene,Oncogene Fusion Proteins,Oncogene Proteins, Chimeric,Fusion Oncogene Proteins,Oncogene Chimeric Proteins,Proteins, Chimeric Oncogene,Proteins, Fusion Oncogene,Proteins, Oncogene Chimeric,Proteins, Oncogene Fusion
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting
D050676 Core Binding Factor Alpha 2 Subunit A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS. AML1A Protein,AML1B Protein,AML1C Protein,AML1D Protein,Acute Myeloid Leukemia 1 Protein,Acute Myeloid Leukemia 1A Protein,Acute Myeloid Leukemia 1B Protein,Acute Myeloid Leukemia 1C Protein,Acute Myeloid Leukemia 1D Protein,Core-Binding Factor Alpha 2 Protein,Pebp2a2 Protein,Runt-Related Transcription Factor 1,Runx1 Protein,Core Binding Factor Alpha 2 Protein,Runt Related Transcription Factor 1

Related Publications

Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
September 2005, Blood,
Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
June 2021, Haematologica,
Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
September 2021, Cancer gene therapy,
Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
April 2004, Blood,
Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
October 2021, Leukemia,
Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
January 2009, Advances in hematology,
Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
October 2007, Cancer genetics and cytogenetics,
Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
January 1986, Progress in clinical and biological research,
Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
June 2013, International journal of hematology,
Yuka Nakamura, and Motoshi Ichikawa, and Hideaki Oda, and Ieharu Yamazaki, and Ko Sasaki, and Kinuko Mitani
July 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!